LLS announces four new Academic Concierge partnerships for cancer drug development

With more than 320 academic science research grants currently in its portfolio, The Leukemia & Lymphoma Society (LLS) has made it a priority to help move promising discoveries more quickly from the laboratory to clinical trial and to patients with cancer.

Bridging the drug development gap faced by our academic researchers by establishing business alliances with leading experts in contract research organizations (CROs) is the foundation of LLS' Academic Concierge Program, an important part of LLS's innovative Therapy Acceleration Program (TAP).  The CROs provide LLS-funded researchers with essential preclinical support, facilitate interactions with the FDA for investigational new drug (IND) applications, and provide clinical trial support.

The LLS today announces four new Academic Concierge partnerships:

  • Ari Melnick, M.D., located at Weill Cornell Medical College in New York, will receive expert CRO support through preclinical development including the application for an IND for a novel peptide inhibitor of the B-cell lymphoma 6 (BCL6) protein aimed at treating patients with diffuse large B-cell lymphoma. LLS support will enable Dr. Melnick to begin a Phase I clinical trial conditionally approved for support through the National Institutes of Health.
  • Christopher Cogle, M.D., located at The University of Florida, and his colleagues will lead a Phase I clinical trial for a targeted drug developed by the biotechnology company OXiGENE. This trial will enroll patients with relapsed and refractory acute myelogenous leukemia and myelodysplastic syndromes. LLS will provide funding for the trial, while OXiGENE will supply drug product and provide clinical monitoring support.
  • Mark Frattini, M.D., Ph.D., located at Memorial Sloan-Kettering Cancer Center and his team, will receive expert CRO preclinical and Phase I clinical trial support to test a novel kinase inhibitor in patients with acute leukemia. This novel drug inhibits the activity of the CDC7 protein, a key regulator of DNA replication. Dr. Frattini will therefore be able to bridge the gap required to move this discovery from his laboratory to the clinic.
  • James DeGregori, Ph.D., located at The University of Colorado, and his colleagues will receive funding to support a Phase I clinical trial, conducted by Christopher Porter, M.D., in which a drug that has been used for indications outside of oncology, cyclosporin A, will be added in combination with dasatinib to treat a rare form of chronic myelogenous leukemia (CML) in which patients become resistant to therapy.  

"Many exciting discoveries have emerged from academic laboratories supported with LLS funding," said Richard Winneker, Ph.D., Senior Vice President for Research. "Now, through our Academic Concierge program, LLS funding can go even further to bring new, much needed therapies to blood cancer patients faster."  


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-based liquid biopsy technology promises early detection of cancer recurrence